ReviewiLIVER2025
Research advances in treatment strategies for breast cancer liver metastases: A comprehensive review.
Review in iLIVER, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond apoptosis: nanomedicine enabled reprogramming of tumor cell death for next-generation radiosensitization.Journal of nanobiotechnology · 2026Review
- Progression-free survival exceeding four years after transarterial embolization for liver metastases from triple-negative breast cancer: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most prevalent malignancy in women globally, with metastatic disease accounting for approximately 90 % of breast cancer-related deaths. The development of breast cancer liver metastases in patients not only significantly reduces survival rates but also severely impairs quality of life. This review systematically examines therapeutic advances in the treatment of breast cancer liver metastases from 2010 to 2023, focusing on novel targeted agents (CDK4/6 inhibitors, PI3K/mTOR pathway inhibitors), immune checkpoint inhibitors, and local interventions. We provide evidence-based recommendations to optimize personalized treatment strategies and improve clinical outcomes for patients with breast cancer liver metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.